April 29, 2021Hypertension
Management of Stage 1 Hypertension in Adults With a Low 10-Year Risk for Cardiovascular Disease: Filling a Guidance Gap: A Scientific Statement From the American Heart Association
Why the study?
Evidence from event-based randomized trials is lacking to guide treatment decisions for many patients with stage 1 hypertension, leaving a guidance gap for those with low 10-year cardiovascular risk.
What are the therapy options for adults with stage 1 hypertension and low 10-year ASCVD risk who fail to meet BP goals after 6 months of lifestyle therapy?
Population
Patients with untreated stage 1 hypertension and 10-year ASCVD risk <10% failing 6 months of lifestyle therapy
Design
American Heart Association scientific statement
Authors
Discussion
Loading...
Member takes
Implication
Offers therapy options after lifestyle failure in low-risk stage 1 hypertension; extends 2017 guidelines into this evidence gap.
Structured PICO
What are the therapy options for adults with stage 1 hypertension and low 10-year ASCVD risk who fail to meet BP goals after 6 months of lifestyle therapy?
P
Population
Adults with untreated stage 1 hypertension (systolic BP/diastolic BP, 130-139/80-89 mm Hg) with a 10-year risk for atherosclerotic cardiovascular disease <10% who fail to meet the systolic BP/diastolic goal (<130/80 mm Hg) after 6 months of guideline-recommended lifestyle therapy
I
Intervention
Therapy options for stage 1 hypertension
This AHA scientific statement provides therapy options for adults with stage 1 hypertension and low ASCVD risk who fail to meet BP goals after 6 months of lifestyle therapy, filling a gap in the 2017 guidelines.
Cite This Study
Jones et al. (2021) conducted a review in Stage 1 hypertension with low 10-year ASCVD risk. Therapy options for stage 1 hypertension was evaluated. This scientific statement provides complementary guidance and therapy options for managing adults with untreated stage 1 hypertension and low ASCVD risk who fail 6 months of lifestyle therapy.